Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-02-14 4:16 pm Sale | 13G | Kinnate Biopharma Inc. KNTE | Nextech V Oncology S.C.S. SICAV-SIF | 0 0.000% | -2,329,480 (Position Closed) | View |
| 2023-02-14 4:32 pm Sale | 13G | Kinnate Biopharma Inc. KNTE | Nextech V Oncology S.C.S. SICAV-SIF | 2,329,480 5.300% | -678,763 (-22.56%) | View |
| 2022-02-14 4:00 pm Sale | 13G | PMV PHARMACEUTICALS INC PMVP | Nextech V Oncology S.C.S. SICAV-SIF | 1,385,807 3.100% | -1,142,483 (-45.19%) | View |
| 2021-02-16 4:00 pm Purchase | 13G | PMV PHARMACEUTICALS INC PMVP | Nextech V Oncology S.C.S. SICAV-SIF | 2,528,290 5.600% | 2,528,290 (New Position) | View |
| 2021-02-16 4:00 pm Purchase | 13G | Kinnate Biopharma Inc. KNTE | Nextech V Oncology S.C.S. SICAV-SIF | 3,008,243 6.900% | 3,008,243 (New Position) | View |
| 2021-02-16 4:00 pm Sale | 13G | IDEAYA Biosciences Inc. IDYA | Nextech V Oncology S.C.S. SICAV-SIF | 0 0.000% | -1,403,823 (Position Closed) | View |
| 2020-02-13 5:06 pm Purchase | 13G | IDEAYA Biosciences Inc. IDYA | Nextech V Oncology S.C.S. SICAV-SIF | 1,403,823 6.900% | 1,403,823 (New Position) | View |
| 2020-02-13 5:06 pm Unchanged | 13G | ARVINAS INC ARVN | Nextech V Oncology S.C.S. SICAV-SIF | 1,694,351 4.300% | 0 (Unchanged) | View |